Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TYR | P14679 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734875 | 1.00 | ALPI (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL216479 | 0.98 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL5281599 | 0.98 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL299866 | 0.95 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17077436 | 0.95 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL25200654 | 0.94 | TYR (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL25180576 | 0.94 | TYR (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL25180579 | 0.94 | TYR (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL23859874 | 0.94 | TYR (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL23510785 | 0.94 | TYR (0.52) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105061230-B | Method for preparing dapoxetine hydrochloride | 康普药业股份有限公司 | 2017-04-26 | — | — | CN | claimed |
| CN-102093578-A | Preparation method of shape-controllable amino-acid ester (with side group benzene ring) substituted polyphosphazene microspheres | UNIV BEIJING CHEMICAL | 2011-06-15 | — | — | CN | claimed |
| CN-121627740-A | 4-Boron as medicine impurity10B) Preparation method of acid-phenylalanine butyl ester hydrochloride | 中子科学(重庆)研究院有限公司 | 2026-03-10 | — | — | CN | disclosed |
| CN-121627740-A | 4-Boron as medicine impurity10B) Preparation method of acid-phenylalanine butyl ester hydrochloride | 中子科学(重庆)研究院有限公司 | 2026-03-10 | — | — | CN | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-4298105-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV Healthcare Company (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| CN-112175031-B | Uridylic acid mixed phosphoramidate compound, pharmaceutical composition and application thereof | 佛山科学技术学院 | 2022-04-26 | — | — | CN | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-5510491-A | 2-PROPENYL CHLOROFORMATE AND DERIVATIVES AS BLOCKING AGENTS FOR AMINO GROUPS OF PEPTIDES DURING PEPTIDE SYNTHESIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0154472-B1 | PROCESS FOR THE PRODUCTION OF L-ASPARTYL-L-PHENYLALANINE ESTER | AJINOMOTO CO., INC. (JP) | 1989-10-11 | — | — | EP | disclosed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
| EP-0154472-A2 | Process for the production of L-aspartyl-L-phenylalanine ester | AJINOMOTO CO., INC. (JP) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | ALPI 1645/4885PKM 2444/4885PTGS1 2951/4885 |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | ALPI 994/4885PKM 3511/4885PTGS1 1430/4885 |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | MC4R, MC1R, MC3R | ALPI 1848/4885PKM 2768/4885PTGS1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.